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Abstract 
Introduction: Adequate hemostasis is crucial for the success of invasive dental treatment, since bleeding problems 
can give rise to complications associated with important morbidity-mortality. The dental treatment of patients who 
tend to an increased risk of bleeding due to the use of anticoagulant and/or antiplatelet drugs raises a challenge in 
the daily practice of dental professionals. Adequate knowledge of the mechanisms underlying hemostasis, and the 
optimized management of such patients, are therefore very important issues.
Objectives: A study is made of the anticoagulant / antiplatelet drugs currently available on the market, with evalua-
tion of the risks and benefits of suspending such drugs prior to invasive dental treatment. In addition, a review is 
made of the current management protocols used in these patients.
Material and Methods: A literature search was made in the PubMed, Cochrane Library and Scopus databases, cove-
ring all studies published in the last 5 years in English and Spanish. Studies conducted in humans and with scien-
tific evidence levels 1 and 2 (metaanalyses, systematic reviews, randomized phase 1 and 2 trials, cohort studies 
and case-control studies) were considered. The keywords used for the search were: tooth extraction, oral surgery, 
hemostasis, platelet aggregation inhibitors, antiplatelet drugs, anticoagulants, warfarin, acenocoumarol.
Results and Conclusions: Many management protocols have been developed, though in all cases a full clinical his-
tory is required, together with complementary hemostatic tests to minimize any risks derived from dental treatment. 
Many authors consider that patient medication indicated for the treatment of background disease should not be 
altered or suspended unless so indicated by the prescribing physician. Local hemostatic measures have been shown 
to suffice for controlling possible bleeding problems resulting from dental treatment.
Key words: Tooth extraction, oral surgery, hemostasis, platelet aggregation inhibitors, antiplatelet drugs, antico-
agulants, warfarin, acenocoumarol.
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Introduction
Hemostasis is a defense mechanism composed of a se-
ries of independent biological systems that aim to pre-
serve vascular integrity and avoid blood losses, while 
ensuring optimum fluidity throughout the circulatory 
system (1,2).
Hemostatic alterations have a broad range of potential 
causes, including deficiency states, hereditary and me-
tabolic alterations, cancer, etc. However, at present, the 
most frequent cause of blood coagulation disorders in 
developed countries is the use of drug substances (3). 
Many drug products are available for the prevention of 
thromboembolic events; it is therefore very important 
for dental professionals to know these products, their 
mechanisms of action, and the measures of caution re-
quired in order to prevent complications.
Tissue damage is generally associated to vascular injury 
resulting in more or less profuse bleeding (2). Vascular 
endothelial rupture exposes different proteins of the su-
bendothelial tissue layer to the bloodstream, triggering 
three different hemostatic mechanisms (2-5):
- Vascular or vasoconstriction phase: Vasoconstriction 
of the damaged blood vessel occurs immediately after 
vascular injury, mediated by the vascular smooth mus-
cle (Fig. 1), and reduces blood loss from the damaged 
vessel. Such vasoconstriction lasts about 20 minutes. 
The vasoconstrictive response alone is not sufficient to 
stop bleeding, but it does have two important effects: it 
reduces blood loss and triggers the second phase, faci-
litating platelet adhesion secondary to exposure of the 
subendothelial collagen fibers and basal membrane of 
the damaged blood vessel wall (2,5).
- Platelet phase, or platelet clot formation: The purpose 
of this phase is to form a primary hemostatic clot com-
posed of aggregated platelets (2) (Fig. 1). Platelets are 
small cell fragments derived from the megakaryocytes 
of the bone marrow, and have a half-life of 7-10 days. 
Their main function is to maintain vascular integrity 
and form a platelet clot in the event of vascular da-
mage (4). The normal count is between 150,000 and 
400,000 platelets/mm3, and the platelet maturation se-
quence lasts 3-5 days (4). The platelets adhere to the 
subendothelial collagen exposed as a result of vascular 
damage, and aggregate to form a platelet clot (4) that 
contributes to reduce blood loss (i.e., bleeding).
- Plasmatic phase, or production of fibrin that stabilizes 
and reinforces the platelet clot (coagulation): This pha-
se is characterized by a complex series of proteolytic 
reactions known as the coagulation cascade. The clas-
sical cascade comprises two pathways: extrinsic and 
intrinsic, which in turn merge to form a common pa-
thway (1).
The plasmatic coagulation phase involves the transfor-
mation of fibrinogen (soluble) into fibrin (insoluble), 
mediated by thrombin – a proteolytic enzyme formed 
by the activation of prothrombin, following sequential 
activation of the coagulation factors (1).
The intrinsic pathway is started by the activation of fac-
tor XII through contact with the subendothelial tissues 
in the damaged zone. The extrinsic pathway in turn is 
started when blood comes into contact with the tissue 
thromboplastin released by the damaged tissues, with 
activation of factor VII. From this point a cascade of me-
tabolic reactions involving different coagulation factors 
is generated, ultimately giving rise to the formation of 
thrombin which, as has been commented above, trans-
forms fibrinogen into fibrin (1,2).
Finally, the blood clot is dissolved in the fibrinolytic 
phase. When the damaged vascular wall is repaired, ac-
tivated factor XII facilitates the conversion of an inacti-
ve plasma molecule to its active form, called kallikrein. 
The latter in turn catalyzes the conversion of inactive 
plasminogen to the active molecule plasmin - an enzy-
me that digests fibrin, yielding degradation products and 
promoting dissolution of the clot. Once fibrin degrada-
tion has been completed, plasmin is quickly neutralized 
by antiplasmin (2,4,5).
Antiplatelet or platelet aggregation inhibitor drugs inhi-
bit the aggregation of platelets, thereby avoiding platelet 
clot formation and suppressing the first hemostatic pha-
se (4). In contrast, anticoagulant drugs inhibit the en-
zyme vitamin K reductase, which mediates conversion 
of vitamin K epoxide to its active form. As a result, the 
formation of coagulation factors dependent upon this 
active form is inhibited, and the coagulation process is 
blocked (6). At clinical level, the end result following 
surgery is the same in both cases, i.e., hemostatic altera-
tion that may result in bleeding which can prove difficult 
to control. As a result, some authors (7,8) recommend 
suspending, reducing or replacing antiplatelet / anticoa-
gulation medication prior to invasive dental treatments, 
while others (9-10) advise against such measures, due to 
Fig. 1. Phases of hemostasis: A) Vascular or vasoconstriction phase. 
B) Platelet phase.
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the possibility of an increased risk of thromboembolic 
events.
The present study offers an update on the different types 
of antiplatelet drugs and anticoagulants currently avai-
lable on the market, with an evaluation of the risks and 
benefits of suspending such drugs prior to invasive den-
tal treatment. In addition, a review is made of the current 
management protocols used in these patients.
Material and Methods 
A literature search was made in the PubMed, Cochra-
ne Library and Scopus databases, using the key words: 
tooth extraction, oral surgery, hemostasis, platelet aggre-
gation inhibitors, antiplatelet drugs, anticoagulants, war-
farin, acenocoumarol, validated by the Mesh and DeCS 
dictionaries, and using the boolean operator “AND” for 
relating the terms in each search.
The search covered all studies published in dental jour-
nals with a relevant impact factor over the last 5 years in 
English and Spanish. Studies conducted in humans and 
with scientific evidence levels 1 and 2 (metaanalyses, 
systematic reviews, randomized phase 1 and 2 trials, co-
hort studies and case-control studies) were considered.
Results and Discussion
An examination of the literature on the subject over the 
last few years reveals a lack of consensus on the way to 
deal with dental patients receiving antiplatelet medica-
tion / anticoagulants.
It remains a recommendation among some authors (7,8) 
to reduce or suspend antithrombotic medication two or 
three days before any dental treatment involving possi-
ble bleeding.
However, in recent years a growing number of investi-
gators have adopted a more conservative approach, pre-
ferring not to interfere with drug treatment (i.e., without 
suspending the medication several days before dental 
treatment or modifying the dosing scheme), and con-
trolling bleeding after the dental procedure by means of 
local hemostatic measures (9-14).
- Anticoagulant drugs and management of anticoagula-
ted patients
Despite their well established efficacy after more than 
50 years on the market, these drugs pose problems in 
the form of adverse effects and interactions with certain 
drug substances and foods. Moreover, although the an-
tithrombotic effect begins 48-72 hours after administra-
tion, reduction of the coagulation factors does not occur 
until 5 days after the start of treatment (6). Consequently, 
the clinical use of these drugs is complicated by the need 
to closely monitor their activity. In effect, anticoagulants 
require correct monitorization and dose adjustment to 
obtain the desired therapeutic effect while minimizing 
the risk of adverse effects associated with both excess 
anticoagulation (bleeding) and insufficient anticoagula-
tion (thrombosis)(6).
1. Coumarin derivatives
• Acenocoumarol or nicumalone (Sintrom® 1 and 4 
mg): The half-life of this drug is quite short (8-10 
hours). It is prescribed as a single daily dose, and is 
the most widely used drug in Spain (6).
• Warfarin sodium (Aldocumar® 10 mg, Coumadin®): 
This is the most widely prescribed oral anticoagulant 
in the United States and the United Kingdom (6). 
It offers prolonged action, with a half-life of 48-72 
hours (6,15,16).
• Ethyl biscumacetate: This drug is not commonly 
used, due to its short lasting action.
• Phenprocoumon: This drug is longer acting than ace-
nocoumarol.
• Fluindione: Little used, and only in France.
2. Indandione derivatives
These are very toxic synthetic drugs, and are therefore 
not used, at least in Spain. They have been associated 
particularly to hypersensitivity reactions (6).
3. Recent introduction on the market
• Dabigatran etexilate (Pradaxa®): This recently mar-
keted drug is a potent inhibitor of free thrombin, 
thrombin bound to fibrin, and platelet aggregation 
induced by thrombin – thereby preventing thrombus 
formation. Its main indication is in elective total hip 
or knee replacement surgery. It is also indicated for 
the prevention of stroke and systemic embolism in 
adults with non-valvular atrial fibrillation (17-19). 
It requires no monitorization (17-20). The drug is 
administered via the oral route in the form of two 
daily doses of 110 mg. Therapy is started 1-4 hours 
after surgery and is maintained for up to 10 days day 
after the operation. Plasma peak concentrations are 
reached between 30 minutes and two hours after 
administration. The bioavailability is 5-6%, and the 
half-life after single and multiple dosing is 8 and 17 
hours, respectively. (17). Most of the drug (80%) is 
excreted in urine (20).
• Rivaroxaban and apixaban (Xarelto®, Eliquis®): These 
are selective factor Xa inhibitors administered via the 
oral route and with an absorption of close to 100%. 
The available clinical data are still limited, and the 
existing information on their metabolism and possi-
ble drug interactions comes mainly from nonclinical 
studies. In the same way as dabigatran, these drugs 
do not require routine monitorization (17,20).
Patients treated with oral anti-vitamin K anticoagulants 
require periodic monitoring, based on the prothrombin 
time (PT). Since this parameter is somewhat imprecise, 
use of the INR (international normalized ratio: propor-
tion between patient PT and control PT, standardized 
and corrected) is currently advised (1,2,5,6,10-16). The 
recommended anticoagulation levels vary between INR 
2-3 for all indications, with the exception of patients 
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with heart valve implants, in which INR should be main-
tained between 2.5-3.5 (2,6).
The literature review identified articles comparing a 
control group with anticoagulant suspension versus an 
experimental group in which anticoagulation is main-
tained. As an example, Evans et al. (21) compared 109 
patients divided into two groups: warfarin was suspen-
ded two days before the operation in one group, and was 
continued in the other group with the maintenance of 
INR 2-4. Mild postoperative bleeding was recorded in 
15 patients who continued warfarin and in 7 patients 
in which warfarin was suspended – the difference be-
ing nonsignificant. Bleeding was controlled by applying 
pressure with a piece of gauze or dressing in the blee-
ding zone.
Méndez et al. (22) adopted a similar procedure but with 
a much smaller study sample. In this case there were 
15 patients in the group in which anticoagulation was 
maintained, and 10 patients in the group in which such 
treatment was suspended two days before the operation. 
Minimum postoperative bleeding was recorded in four 
of the patients in which anticoagulation was maintained, 
and in none of the controls. However, the small sample 
size did not allow the recording of statistically signifi-
cant results.
Al-Mubarack et al. (23) in turn compared 214 patients 
distributed into four groups, establishing a combination 
between warfarin suspension and continuation, with 
or without suture application. These authors observed 
slightly greater bleeding immediately after tooth extrac-
tion in the two groups in which warfarin was maintai-
ned. The number of cases was not specified, though the 
differences were described as nonsignificant. 
Sacco et al. (10) compared an experimental group in 
which anticoagulation was not suspended versus a con-
trol group in which dose reduction was indicated two 
days before the operation. These authors recorded no 
cases of immediate bleeding, though bleeding was ob-
served two hours after the operation, and proved slightly 
greater in the experimental group.
Bajkin et al. (11) likewise found no significant diffe-
rences on comparing two groups of approximately 110 
patients each (anticoagulation being suspended three 
days before surgery in one group and maintained in the 
other).
As indicated by these results, no significant differences 
are observed in the prevalence of bleeding in one group 
versus the other – thus supporting the opinion of the abo-
ve authors that it is not necessary to either suspend or 
reduce anticoagulation in the context of minor surgery, 
since local hemostatic measures suffice to minimize 
bleeding.
On the other hand, in the case of elective surgery, ma-
jor surgery (over three extractions, implant placement, 
etc.), INR > 3.5 and other concomitant risk factors, the 
protocol of choice is to suspend anticoagulation 2-3 days 
before surgery (depending on the risk of thromboembo-
lism), or to switch to subcutaneous heparin (6)(Fig. 2).
Fig. 2. Management algorithm for patients with anticoagulation thera-
py scheduled for invasive dental treatment. OAC: oral anticoagulant; 
LMWH: low molecular weight heparin.
Regarding the new oral anticoagulant drugs, the data in 
relation to dental treatment are still limited, since the-
se drugs have only recently appeared on the market. In 
principle, it seems that there is no need to suspend anti-
coagulation or modify the dose in the case of operations 
with a normal or low bleeding risk (simple extractions, 
operations lasting under 45 minutes)(17,19,24).
In the case of major surgery or procedures involving a 
high bleeding risk (multiple extractions, operations las-
ting > 45 minutes, head and neck cancer surgery)(24), 
the recommendation is to suspend the medication 24 
hours before the operation and to reintroduce it after 
24 hours, provided good hemostasis has been achieved 
(17,19). In contrast, Spyropoulus et al. (24) in these ca-
ses advises anticoagulant suspension 2-3 days before the 
operation – though the authors underscore the need to 
carry out more studies and to investigate the possible 
effects of these new drugs.
Apart from their rapid action and few interactions, one 
of the main advantages of the new anticoagulants seems 
to be that they require no monitorization (17,19,24,25). 
Nevertheless, there are situations in which we need to 
know whether the level of anticoagulation is correct, e.g., 
in emergency surgery, to assess treatment compliance, 
or even to reassure the patient that the anticoagulation 
levels are correct (25). In these cases both activated par-
tial thromboplastin time (aPTT) and thrombin time (TT) 
may prove useful (17,25).
- Antiplatelet drugs and management of patients with 
antiplatelet medication
Antiplatelet drugs are generally prescribed for the pre-
vention of arterial and venous thrombosis in patients 
with ischemic heart disease, heart valve implants and 
stents, and in people at risk of suffering cerebrovascular 
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events such as stroke. Since these drugs act by inhibiting 
platelet function, they have been accepted as adequate 
antithrombotic treatment (26). The main antiplatelet 
drugs marked in Spain are the following:
• Acetylsalicylic acid (ASA)(Aspirin®, Adiro®, Bio-
pak®, Tromalyt®) blocks thromboxane A2 produc-
tion, thereby inhibiting cyclooxygenase activity and 
consequently platelet aggregation (4). The effect of 
this drug upon the platelets is irreversible, and the-
refore lasts for the full length of platelet life (7-10 
days). Low doses (75-100 mg) are generally indica-
ted in cases of chest pain, ischemia, transient ische-
mic accidents, and during the postoperative period 
(post-angioplasty / angiography)(27).
• Clopidogrel bisulfate (Plavix®, Iscover®) inhibits 
platelet aggregation by blocking ADP binding to its 
platelet receptor and subsequent activation of the 
GPIIb-IIIa complex mediated by ADP (4,27).
 • Ticlopidine hydrochloride (Tiklid®, Ticlodone®) in-
hibits platelet binding to ADP-fibrinogen, along with 
posterior platelet-platelet binding (aggregation)(4).
• Dipyridamole (Persantin®) blocks adenosine transport 
in platelets, erythrocytes and endothelial cells. The 
resulting increase in the local extracellular concen-
trations of adenosine acts directly upon the platelet 
A2-receptors, increasing the platelet cyclic adenosi-
ne monophosphate (cAMP) levels and consequently 
blocking platelet aggregation (4,27).
• Triflusal (Disgren®) is an acetylsalicylic acid (aspirin) 
analog that blocks platelet aggregation by irreversi-
bly inhibiting platelet cyclooxygenase (26).
Because of their potential bleeding effect, antiplate-
let drugs are often interrupted during the perioperative 
period, without adequately evaluating the increased 
thrombotic risk of this decision. More recent publica-
tions suggest that the increase in bleeding risk induced 
by antiplatelet drugs has been exaggerated, while at the 
same time the increased thrombotic risk associated with 
treatment interruption has been underestimated (28). 
Consequently, although each invasive dental procedure 
implies a risk of oral bleeding, it is not advisable to in-
terrupt antiplatelet therapy, since the increased risk of 
thromboembolism could outweigh the risk of bleeding 
(26-28).
Madan et al. (27) studied 51 patients subjected to anti-
platelet treatment with low-dose ASA (75-100 mg). The 
medication was not suspended in any of the patients, and 
in no case was bleeding observed. As hemostatic measu-
res, the authors used surgical gauze impregnated with a 
feracrylum solution, and 3/0 sutures.
In the same line of research, Aframian et al. (28) con-
cluded that patients administered low-dose ASA can 
undergo any type of oral treatment, minor surgery and/
or tooth extractions, without having to suspend the anti-
platelet medication, and without this decision implying 
any added risk for the patients – local hemostatic mea-
sures being more than enough to secure bleeding control 
(27,28). 
In 2008, Krishnan et al. (29) conducted a study of 82 
patients divided into three groups. Antiplatelet treatment 
was suspended in 35 of the patients 10 days before sur-
gery. The authors observed no significant differences 
among the groups, since none of them showed prolon-
ged or significant bleeding in the operated zone. 
Similar results have been reported by Morimoto et al. 
(13) in their study of 87 patients in which no increase in 
bleeding rate was observed despite continuation of their 
regular drug treatment.
Our literature review identified few studies of patients 
receiving two antiplatelet drugs simultaneously. Some 
authors have reported no increased bleeding tendency 
in such patients compared with individuals receiving a 
single antiplatelet drug (3,4). In contrast, Scharf (30) re-
ported that dual antiplatelet treatment is associated with 
a 40-50% increase in bleeding risk compared with single 
drug treatments.
Lillis et al. (26), in a study of 33 patients receiving two 
antiplatelet drugs and 78 patients with antiplatelet mo-
notherapy, recorded 22 cases of bleeding in the former 
group versus only two cases in the single drug treatment 
group. Although the difference was significant, the au-
thors concluded that all of the cases of bleeding were 
easily controlled by local measures.
Among patients receiving dual antiplatelet treatment, 
special attention should focus on those carrying both 
conventional and drug-eluting stents (27,29,30). 
Although the predominant recommendation in patients 
receiving dual therapy is to suspend one of the two anti-
platelet drugs (generally clopidogrel) between 3-5 days 
before the operation (31), with reintroduction 24 hours 
after surgery, we should avoid early discontinuation of 
one of the two drugs at least during the first year in such 
individuals. In these cases it is essential to consult the 
professional who prescribed the medication (30,31). 
On the other hand, the results published by Lillis et al. 
(26) support the safety of dental extractions without inte-
rruptions in either simple or dual antiplatelet treatment, 
with the adoption of adequate local hemostatic measu-
res.
- Postoperative recommendations and local hemostatic 
agents
Scully and Wolff (32), in coincidence with many other 
authors (6,10,13,14), recommend performing all dental 
surgeries in the morning, in order to be able to resolve 
any bleeding complications in the course of the day.
The following patient instructions are advised (11,31-
33):
• Apply pressure with a piece of gauze for 30-40 mi-
nutes
• Avoid oral rinses during the first 24 hours
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• Follow a soft and cold diet during the first 24 hours
• Avoid suctioning movements
• Avoid touching the socket region with the tongue or 
manipulation of the operated zone
The adoption of adequate hemostatic measures is the key 
to not having to modify the antiplatelet or anticoagula-
tion treatment in most cases. The incidence of postope-
rative bleeding episodes that cannot be controlled by 
such measures varies between 0-3.5% (33).
As hemostatic measures, some authors recommend tra-
nexamic acid (Amchafibrin®) as a postoperative rinse 
to stabilize the blood clot, since it inhibits plasminogen 
activation and fibrinolysis (21,22,28,31) and appears 
to have few side effects (nausea, diarrhea, orthostatic 
hypotension)(22). Rinses are advised twice a day during 
the first 48 hours – affording adequate hemostasis after 
minor surgery (28). In contrast, other authors such as Sa-
lam et al. (34) and Ferrieri et al. (9) prefer to use sterile 
gauze impregnated tranexamic acid rather than tranexa-
mic acid rinses, arguing that the risk of clot dissolution 
as a result of the mechanical rinsing action outweighs 
the benefits of the antifibrinolytic agent. On the other 
hand, it must be mentioned that in some countries tra-
nexamic acid either has not been approved for local he-
mostasis (as in Japan)(13) or is not fully accessible (as in 
the United Kingdom). This has favored the use of other 
alternative hemostatic measures (21). 
Other widely used hemostatic agents are intraalveolar 
oxidized cellulose (Surgicel®), reabsorbable collagen 
sponges (Octocolagen®, Gelatamp® from Roeko), fibrin 
adhesive (Tissucol®) or tissue adhesives (Tisuacryl® 
from Dentsplay) and, of course, sutures. 
Bajkin et al. (11) and Bacci et al. (12) compared groups 
of patients with different hemostatic measures with the 
purpose of assessing their effectiveness against blee-
ding. None of the authors found any given measure to be 
superior to the rest (11-13).
In relation to suturing, there are differing opinions re-
garding the ideal type of suture for minimizing bleeding. 
Some authors advocate reabsorbable sutures since they 
do not have to be removed – thereby avoiding trauma 
and minimizing bleeding risk (2,12,28). In contrast, 
other investigators prefer non-reabsorbable silk sutures, 
since they retain much less plaque and therefore greatly 
lessen the risk of bacterial penetration into the bloods-
tream (23). This in turn reduces the risk of postoperative 
complications such as thromboembolic phenomena or 
infections (13-15).
Conclusions
In cases of invasive dental treatment (extractions or minor 
surgery), patient medication indicated for the treatment 
of background disease should not be altered or suspen-
ded unless so indicated by the prescribing physician. Lo-
cal hemostatic measures are shown to suffice to control 
possible bleeding secondary to dental treatments. 
Although bleeding complications are a source of con-
cern and discomfort, they do not involve the same risks 
for patients as thromboembolic complications.
We have found no standardized protocol defining opti-
mum management of these patients, though most authors 
coincide that patient health and safety must be the prio-
rity concern in all cases. In this context it is necessary 
to carefully evaluate the bleeding risk of the planned 
treatment, as well as the thrombotic risk of suppressing 
the anticoagulant or antiplatelet medication, on an indi-
vidualized basis for each patient, with a view to provi-
ding optimum and personalized care.
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